SEC Form 4 · accession 0001209191-18-036178
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James J Vaughn
Officer — Chief Commercial Officer
Period of report
Jun 4, 2018
Accepted (ET)
Jun 6, 2018 · 7:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 4, 2018 | M | 9,000 | $22.98 | A | 38,655 | D | |
| Common StockF2,F3,F4,F1 | Jun 4, 2018 | S | 9,000 | $43.8708 | D | 29,655 | D | |
| Common StockF1 | Jun 4, 2018 | M | 13,500 | $27.48 | A | 43,155 | D | |
| Common StockF2,F3,F5,F1 | Jun 4, 2018 | S | 10,977 | $44.6691 | D | 32,178 | D | |
| Common StockF2,F3,F6,F1 | Jun 4, 2018 | S | 2,523 | $45.4689 | D | 29,655 | D | |
| Common StockF1 | Jun 4, 2018 | M | 20,000 | $27.00 | A | 49,655 | D | |
| Common StockF2,F3,F7,F1 | Jun 4, 2018 | S | 7,552 | $46.0652 | D | 42,103 | D | |
| Common StockF2,F3,F8,F1 | Jun 4, 2018 | S | 12,448 | $46.8261 | D | 29,655 | D | |
| Common StockF1 | Jun 4, 2018 | M | 16,268 | $28.05 | A | 45,923 | D | |
| Common StockF2,F3,F9,F1 | Jun 4, 2018 | S | 9,639 | $47.5743 | D | 36,284 | D | |
| Common StockF2,F3,F10,F1 | Jun 4, 2018 | S | 6,629 | $48.3285 | D | 29,655 | D | |
| Common StockF1 | Jun 4, 2018 | M | 12,000 | $29.34 | A | 41,655 | D | |
| Common StockF2,F3,F11,F1 | Jun 4, 2018 | S | 12,000 | $48.5736 | D | 29,655 | D | |
| Common StockF1 | Jun 4, 2018 | M | 10,000 | $17.18 | A | 39,655 | D | |
| Common StockF12,F3,F13,F1 | Jun 4, 2018 | S | 10,000 | $43.4088 | D | 29,655 | D | |
| Common StockF12,F3,F14,F1 | Jun 4, 2018 | S | 8,594 | $43.4209 | D | 21,061 | D | |
| Common StockF12,F3,F15,F1 | Jun 4, 2018 | S | 4,052 | $43.542 | D | 17,009 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F16 | $17.18 | Jun 4, 2018 | M | 10,000 | D | — | Feb 18, 2020 | Common Stock | 0 | 0 | D |
| Employee Stock Option (right to buy)F17 | $22.98 | Jun 4, 2018 | M | 9,000 | D | — | Jan 27, 2021 | Common Stock | 0 | 0 | D |
| Employee Stock Option (right to buy)F18 | $29.34 | Jun 4, 2018 | M | 12,000 | D | — | Feb 5, 2022 | Common Stock | 0 | 0 | D |
| Employee Stock Option (right to buy)F19 | $28.05 | Jun 4, 2018 | M | 16,268 | D | — | Jan 31, 2023 | Common Stock | 0 | 3,732 | D |
| Employee Stock Option (right to buy) HoldingF20 | $27.00 | Jun 4, 2018 | M | 20,000 | D | — | Feb 16, 2026 | Common Stock | 0 | 41,700 | D |
| Employee Stock Option (right to buy) HoldingF21 | $27.48 | Jun 4, 2018 | M | 13,500 | D | — | Jan 31, 2027 | Common Stock | 0 | 40,580 | D |
Explanation of responses
- F1Includes an aggregate of 15,534 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F10Represents weighted average sale price. Actual sale prices ranged from $48.16 to $48.40.
- F11Represents weighted average sale price. Actual sale prices ranged from $48.40 to $48.79.
- F12These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 8, 2017.
- F13Represents weighted average sale price. Actual sale prices ranged from $43.20 to $43.51.
- F14Represents weighted average sale price. Actual sale prices ranged from $43.25 to $43.68.
- F15Represents weighted average sale price. Actual sale prices ranged from $43.51 to $43.66.
- F16The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.
- F17The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter.
- F18The option became exercisable as to 25% of the shares on February 5, 2013, and became exercisable as to 1/48th of the shares each full month thereafter.
- F19The option became exercisable as to 25% of the shares on January 31, 2014, and becomes exercisable as to 1/48th of the shares each full month thereafter.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 9, 2018.
- F20The option became exercisable as to 25% of the shares on February 16, 2017, and became exercisable as to 1/48th of the shares each full month thereafter.
- F21The option became exercisable as to 25% of the shares on January 31, 2018, and becomes exercisable as to 1/48th of the shares each full month thereafter.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $43.68 to $44.23.
- F5Represents weighted average sale price. Actual sale prices ranged from $44.23 to $45.14.
- F6Represents weighted average sale price. Actual sale prices ranged from $45.32 to $45.61.
- F7Represents weighted average sale price. Actual sale prices ranged from $45.61 to $46.60.
- F8Represents weighted average sale price. Actual sale prices ranged from $46.64 to $47.10.
- F9Represents weighted average sale price. Actual sale prices ranged from $47.10 to $48.08.